Emd Serono Research & Development Institute, Inc.

This early-stage study tested a new drug called M9466 combined with chemotherapy for people with advanced solid tumors, including colorectal cancer. The main goal was to check safety and find the right dose. The study was stopped early and only enrolled 3 participants, so no stro…

This study tested whether adding the drug Debio 1143 (Xevinapant) to standard chemoradiation helps people with advanced head and neck cancer live longer without the disease getting worse. The trial planned to enroll 730 adults with untreated, locally advanced squamous cell carcin…

This study tested whether adding the drug xevinapant to standard radiation therapy could help prevent head and neck cancer from coming back after surgery. It included 166 people with a high risk of relapse who could not take the usual chemotherapy drug cisplatin. The trial was st…

This early-stage study tested a new drug called M1069 in 15 people with advanced solid tumors that had spread or couldn't be removed. The main goal was to check safety and find the right dose. The study was stopped early, so results are limited.

This early-phase study tested whether adding an experimental drug called xevinapant to standard weekly chemotherapy and radiation was safe and tolerable for people with advanced head and neck cancer. It involved 18 participants with cancer that could not be removed by surgery. Th…